---
title: "Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293777709.md"
description: "Maxim Group analyst Naz Rahman reiterated a Buy rating on Nuvectis Pharma (NVCT) with a $30.00 price target. This follows H.C. Wainwright also maintaining a Buy rating with a higher $39.00 target. Rahman, who covers the healthcare sector, has a historical success rate of 36.93% on recommended stocks."
datetime: "2026-07-24T15:36:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293777709.md)
  - [en](https://longbridge.com/en/news/293777709.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293777709.md)
generator: "portal-rs"
---

# Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $30.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Rahman covers the Healthcare sector, focusing on stocks such as Nuvectis Pharma, Vertex Pharmaceuticals, and Vivani Medical. According to TipRanks, Rahman has an average return of -7.5% and a 36.93% success rate on recommended stocks. 

In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $39.00 price target.

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [VANI.US](https://longbridge.com/en/quote/VANI.US.md)

## Related News & Research

- [Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)](https://longbridge.com/en/news/297912026.md)
- [Nuvectis Pharma to present at H.C. Wainwright annual investment conference](https://longbridge.com/en/news/297909736.md)
- [Morgans Remains a Buy on EchoIQ Limited (EIQ)](https://longbridge.com/en/news/297720502.md)
- [09:01 ETHealthcare Is Moving Into the Home. Home Accessibility Now Has a Validated Score.](https://longbridge.com/en/news/297656740.md)
- [Cantor Fitzgerald Sticks to Its Buy Rating for EDreams ODIGEO (0QS9)](https://longbridge.com/en/news/297794987.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**